AGARWALEYE · NSE
Dr. Agarwal's Health Care Limited
₹500.45
+0.06% (+₹0.3)
Prev. close
₹500.15
Volume
1,05,331
Delivery %
57.0%
As of
18 Sept 2026
Price history
Jefferies Analysis · Jefferies · 20 Aug 2026
“Upgraded Dr. Agarwal's Health Care to 'buy' from 'hold' on August 5, with a target of ₹600 per share, indicating a 19.6% upside from its previous close. This suggests a strong conviction in the stock's future performance.”
Published mid-session at 12:57 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Upgraded Dr. Agarwal's Health Care to 'buy' from 'hold' on August 5, with a target of ₹600 per share, indicating a 19.6%…” | Jefferies AnalysisJefferies | Dr. Agarwal's Health Care | PENDING | ||||
“Upgraded Dr. Agarwal's Health Care to 'buy' from 'hold' on August 5, with a target of ₹600 per share, indicating a 19.6% upside from its previous close. This suggests a strong conviction in the stock's future performance.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
Fundamentals
About Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Dr. Adil Agarwal M.B.B.S, M.S, MBA
Headquarters
Chennai
Website
dragarwals.co.inExchange
View on NSE ↗Key stats
Market cap
₹15,863.42 Cr
P/E ratio (TTM)
107.6
EPS (TTM)
₹4.65
Beta (1Y · daily vs NIFTY 50)
0.30
Shares float
12.10 Cr
EPS · quarter ended Jun 2026
₹1.42
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹1,016.48 Cr | ₹1,327.67 Cr | ₹1,711.00 Cr | ₹2,080.08 Cr | |
| EBITDA | — | — | ₹283.86 Cr | ₹406.56 Cr | ₹499.38 Cr | ₹615.34 Cr |
| ₹-55.00 Cr | ₹38.00 Cr | ₹94.10 Cr | ₹83.06 Cr | ₹83.46 Cr | ₹133.19 Cr | |
| Diluted EPS | — | — | ₹2.98 | ₹2.63 | ₹2.78 | ₹4.18 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹787.00 Cr | ₹1,025.00 Cr | ₹1,823.00 Cr | ₹2,751.00 Cr | ₹3,665.00 Cr | ₹3,942.00 Cr | |
| — | — | ₹857.35 Cr | ₹966.44 Cr | ₹960.91 Cr | ₹1,066.20 Cr | |
| Stockholders' equity | ₹184.00 Cr | ₹213.00 Cr | ₹630.00 Cr | ₹1,339.00 Cr | ₹1,867.00 Cr | ₹2,026.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹99.00 Cr | ₹164.00 Cr | ₹233.00 Cr | ₹346.00 Cr | ₹360.00 Cr | ₹519.00 Cr | |
| Investing cash flow | — | — | ₹-509.09 Cr | ₹-913.91 Cr | ₹-750.31 Cr | ₹-308.45 Cr |
| ₹-37.00 Cr | ₹35.00 Cr | ₹303.00 Cr | ₹553.00 Cr | ₹382.00 Cr | ₹-220.00 Cr | |
| Capital expenditure | ₹-127.00 Cr | ₹-71.00 Cr | ₹-158.00 Cr | ₹-232.00 Cr | ₹-321.00 Cr | ₹-461.00 Cr |
| End cash position | — | — | ₹126.98 Cr | ₹111.75 Cr | ₹100.40 Cr | ₹90.55 Cr |
Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Feb 25–Mar 25(2Q) | Jun 25–Sep 25(2Q) | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| Promoter | 32.45% | 32.42% | 32.39% | 32.36% | 32.34% |
| Public | 67.55% | 67.58% | 67.61% | 67.64% | 67.66% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Dr. Agarwal's Health Care Limited | ₹16,007.64 Cr | ₹500.15 | 108.1 | 7.90 | 6.6% | 0.53 | +21.9% | +13.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
3 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.
Dr. Agarwal's Health Care: New Pledge Over 2.38% Shares
A new pledge was created over 7,538,303 equity shares of Dr. Agarwal’s Health Care Limited, representing 2.38% of its share capital. Catalyst Trusteeship Limited, as the onshore security agent, reported this pledge on August 21, 2026. This action follows the release of a previous pledge on a larger block of shares.